IMPEDIMED LIMITED — Investor Relations & Filings

ImpediMed Limited is a medical technology company specializing in the development and commercialization of non-invasive devices utilizing bioimpedance spectroscopy (BIS) technology. The company's core focus is the early detection and management of secondary lymphedema in oncology patients, particularly those undergoing treatment for breast cancer. Its flagship product, the SOZO digital health platform, provides rapid and precise measurements of extracellular fluid, total body water, and body composition. Beyond oncology, the technology is applied to the clinical monitoring of chronic heart failure and other conditions characterized by fluid imbalance. By delivering actionable data through its BIS technology, ImpediMed enables clinicians to implement early interventions and personalized care strategies. The platform is designed for seamless integration into clinical workflows to support longitudinal patient assessment.